ASCO® 2023 Insights: "Determinants of Resistance to Nivo Monotherapy Investigated Through Genomic and Transcriptomic Analysis of RCC Tumors From the HCRN GU16-260 Study"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
David Braun
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
David Braun
Login to view comments.
Click here to Login